Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05652335
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Who this might be right for
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC 180
Testing effectiveness (Phase 2)Ended earlyNCT01118013
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Who this might be right for
LeukemiaLymphomaLymphoproliferative Disorder+3 more
Alliance for Clinical Trials in Oncology 6
Early research (Phase 1)Study completedNCT01556438
What this trial is testing

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Eli Lilly and Company 16
Testing effectiveness (Phase 2)Study completedNCT02751255
What this trial is testing

Daratumumab in Combination With ATRA

Who this might be right for
Multiple Myeloma
Amsterdam UMC, location VUmc 60
Not applicableNot Yet RecruitingNCT07015021
What this trial is testing

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

Who this might be right for
Multiple MyelomaCarfilzomibDaratumumab+1 more
The First Affiliated Hospital of Soochow University 72
Early research (Phase 1)Study completedNCT00113204
What this trial is testing

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Infinity Pharmaceuticals, Inc. 18
Large-scale testing (Phase 3)Study completedNCT00063726
What this trial is testing

PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 600
Testing effectiveness (Phase 2)UnknownNCT06255847
What this trial is testing

Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM

Who this might be right for
Multiple Myeloma in Relapse
Shanxi Bethune Hospital 43
Very early researchUnknownNCT05016778
What this trial is testing

CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
Zhejiang University 15
Early research (Phase 1)Not Yet RecruitingNCT07725406
What this trial is testing

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (MM)
Weill Medical College of Cornell University 32
Not applicableUnknownNCT04004338
What this trial is testing

Carfilzomib in Combination for the Treatment of RR MM

Who this might be right for
Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma
Black Sea Hematology Association 300
Testing effectiveness (Phase 2)Study completedNCT00053989
What this trial is testing

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+5 more
Roswell Park Cancer Institute 41
Early research (Phase 1)Study completedNCT05243342
What this trial is testing

Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 18
Not applicableUnknownNCT05297240
What this trial is testing

Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

Who this might be right for
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
PETHEMA Foundation 170
Early research (Phase 1)Looking for participantsNCT07105059
What this trial is testing

Teclistamab and Mezigdomide in People With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT00823524
What this trial is testing

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+6 more
Asan Medical Center 47
Early research (Phase 1)Ended earlyNCT05641324
What this trial is testing

ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Who this might be right for
Multiple MyelomaRelapsed CancerRefractory Multiple Myeloma+2 more
Anaveon AG 4
Early research (Phase 1)Study completedNCT02043847
What this trial is testing

TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

Who this might be right for
Multiple Myeloma, RelapsedMultiple Myeloma, Refractory to Standard Treatment
University of Illinois at Chicago 12
Large-scale testing (Phase 3)Study completedNCT00003687
What this trial is testing

Treatment for Chronic Pain in Patients With Advanced Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+6 more
NCIC Clinical Trials Group 87
Testing effectiveness (Phase 2)Active Not RecruitingNCT02899052
What this trial is testing

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
AbbVie 120
Next Page